Boehringer Ingelheim has unveiled its latest offering for the poultry industry with the launch of Vaxxilive Cocci 3, a coccidiosis vaccine previously recognized as Hatchpak Cocci III. This biological alternative to in-feed anticoccidial drugs aims to effectively prevent coccidiosis while prioritizing the well-being of birds.
Vaxxilive Cocci 3 operates by stimulating the bird’s natural immune response, minimizing tissue damage, and presenting a robust defense against coccidiosis. The vaccine incorporates a proven formula, including three genetically stable precocious strains of the Eimeria species affecting broilers. Notably, these precocious strains boast shortened life cycles, enabling earlier immunity development compared to non-precocious strains.
The accelerated turnover rate of precocious strains results in reduced oocyst production and less tissue damage, contributing to better immunity while preserving barrier integrity and minimizing vaccine reactions. Vaxxilive Cocci 3 stands out as a year-round solution, offering improved coccidiosis management with a reduced risk of chemical resistance development compared to protocols involving vaccination, chemical treatment, and feed additives.
In addition to the vaccine’s efficacy, Boehringer Ingelheim has introduced process innovations, enhancing manufacturing procedures for more consistent and quality production. Rick Phillips, DVM, Director of Key Account Veterinarians for Boehringer Ingelheim Poultry, emphasizes the importance of product selection and expert support. He states, “As with any vaccination, choosing a product is only half the battle,” highlighting the commitment of Boehringer Ingelheim’s field team to provide industry-leading support, including regular visits to review vaccination protocols and maintain comprehensive poultry health programs.
Vaxxilive Cocci 3 is now readily available, marking a significant advancement in the poultry industry’s ongoing efforts to combat coccidiosis and promote sustainable poultry health.
